Cell and gene therapy CRO market Growth Opportunity and Industry Forecast to 2035 Characterized by high prevalence rate of rare and genetic disorders, and rise in demand for effective novel ATMPs, the cell and gene therapy contract research industry is likely to witness evolutionary advancements, in the coming years Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell and Gene Therapy CROs Market, 2022-2035”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed overview of the overall market landscape of the cell and gene therapy CROs, based on several relevant parameters, such as year of establishment, company size, location of headquarters, area of expertise, scale of operation and types of services offered.  A detailed analysis on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies.  Elaborate profiles of key industry players based in North America, Europe and Asia-Pacific that offer contract research services.  A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies.  An analysis of the recent collaborations within the cell and gene therapy contract research industry, during the period 2015-2022.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2022.  A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015.  A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Area of Expertise  Cell Therapy  Gene Therapy  Scale of Operation  Preclinical  Clinical  Drug Discovery  Therapeutic Area  Oncological Disorders  Neurological Disorders  Cardiovascular Disorders  Infectious Diseases  Metabolic Disorders  Autoimmune Disorders  Blood Disorders  Rare / Genetic Disorders  Ophthalmic Disorders  Other disorders  Analysis by Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa Key companies covered in the report  Altasciences  Charles River Laboratories  Creative Biolabs  IQVIA  Medpace  PPD  Precision for Medicine  Accelera  Evotec  ICON  Syneos Health  CMIC Group  Labcorp To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html News article AI-based digital pathology market Learn from experts: do you know about these emerging industry trends? TCR Therapies: An Emerging Therapeutic Modality Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #atmps #genetherapycro #cellandgenetherapycompanies #MarketResearch #MarketInsights

The cell and gene therapy CROs market is anticipated to grow at an annualized rate of 18% by 2035, claims Roots Analysis Characterized by high prevalence rate of rare and genetic disorders, and rise in demand for effective novel ATMPs, the cell and gene therapy contract research industry is likely to witness evolutionary advancements, in the coming years. Roots Analysis has announced the addition of Cell and Gene Therapy CRO Market , 2022-2035” report to its list of offerings. In order to mitigate the challenges associated with the cell and gene therapies research and development, around 50-60% of the developers prefer to outsource their operations to contract research organizations (CROs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. The aforementioned challenges are believed to be the key factors for driving the outsourcing of research operations to a cell and gene therapy CRO , which claim to be well-aware of the nuances of advanced therapy medicinal products (ATMP) design and development, as well as cell and gene therapy manufacturing process. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/230/request-sample.html Key Market Insights Presently, more than 105 players claim to offer cell and gene therapy contract research services This segment of the industry is dominated by the presence of mid-sized (51-500 employees) and small (2-51 employees) players, which collectively represent more than 70% of the total CROs in this domain. In addition, about 20% of the firms were founded post 2010. >40% of the players carry out contract research operations across preclinical and clinical scales Nearly 21% of the total industry stakeholders have the required capabilities for cell and gene therapies at the commercial scale. In addition, 16% CROs are capable of providing contract research services for discovery purposes. Partnership activity in this domain has increased at a CAGR of over 61%, during 2015- 2022 Acquisitions and mergers emerged as the most popular type of partnership model adopted by industry stakeholders (54%), followed by service agreements (20%). Further, most of the deals were inked by players based in North America (58%). Over 32 mergers and acquisitions were established in this domain, during the period 2015-2022 It was observed that majority of the deals were intracontinental (72%), involving participants from different countries. Geographical consolidation and portfolio addition were observed to be the major key value drivers of M&A activity, followed by service portfolio and geographical expansion (28%, each). More than 1,330 clinical trials evaluating cell and gene therapies have been registered worldwide Of the total, close to 79% of the studies are active and recruiting patients, followed by those that have already been completed (7%). It is important to highlight that more than 20% of cell and gene therapy focused-clinical trials are currently in phase II. North America and Europe are anticipated to capture over 75% of the market share, in 2035 In terms of scale of operation, the current market is driven by clinical operations (55%); this trend is unlikely to change in the foreseen future as well. Further, based on area of expertise, majority of the revenue share (61%) of the overall market in 2035 is likely to be driven by cell therapies. For additional details, please visit https://www.rootsanalysis.com/reports/view_document/cell-and-gene-therapy-cros-market/230.html You may also be interested in the following titles: 1. Gene Therapy Market: (5TH Edition) Industry Trends and Global Forecasts, 2022-2035 2. RNA Sequencing Services Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. Contact: Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com